Intracoronary Compared to Intravenous Abciximab and High-Dose Bolus Compared to Standard Dose in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Transradial Primary Percutaneous Coronary Intervention: a Two-by-Two Factorial Placebo-Controlled Randomized Study

American Journal of Cardiology

Volumn 105, Issue 11, 2010, Pages 1520-1527

  Bertrand, Olivier F ^a   Rodés Cabau, Josep ^a   Larose, Éric ^a   Rinfret, Stéphane ^a   Gaudreault, Valérie ^a   Proulx, Guy ^a   Barbeau, Gérald ^a   Déry, Jean Pierre ^a   Gleeton, Onil ^a   Manh Nguyen, Can ^a   Noël, Bernard ^a   Roy, Louis ^a   Costerousse, Olivier ^a   De Larochellière, Robert ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; BIOLOGICAL MARKER; CLOPIDOGREL; CYPHER; PLACEBO; RAPAMYCIN; UNCLASSIFIED DRUG;

ACUTE DISEASE; ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG MEGADOSE; FACTORIAL DESIGN; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART MUSCLE NECROSIS; HEART MUSCLE PERFUSION; HUMAN; INTRACORONARY INFUSION; MAJOR CLINICAL STUDY; MALE; NO REFLOW PHENOMENON; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT REFERRAL; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SYMPTOMATOLOGY; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; HEART CONDUCTION SYSTEM; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRA-ARTERIAL; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; TREATMENT OUTCOME;

EID: 77952419897     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2010.01.006     Document Type: Article

References (28)

1. Hallen J., Buser P., Schwitter J., Petzelbauer P., Geudelin B., Fagerland M.W., Jaffe A.S., and Atar D. Relation of cardiac troponin I measurements at 24 and 48 hours to magnetic resonance-determined infarct size in patients with ST-elevation myocardial infarction. Am J Cardiol 104 (2009) 1472-1477
2. Giannitsis E., Steen H., Kurz K., Ivandic B., Simon A.C., Futterer S., Schild C., Isfort P., Jaffe A.S., and Katus H.A. Cardiac magnetic resonance imaging study for quantification of infarct size comparing directly serial versus single time-point measurements of cardiac troponin T. J Am Coll Cardiol 51 (2008) 307-314
3. Chia S., Senatore F., Raffel O.C., Lee H., Wackers F.J., and Jang I.K. Utility of cardiac biomarkers in predicting infarct size, left ventricular function, and clinical outcome after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. JACC Cardiovasc Interv 1 (2008) 415-423
4. Tarantini G., Razzolini R., Cacciavillani L., Bilato C., Sarais C., Corbetti F., Marra M.P., Napodano M., Ramondo A., and Iliceto S. Influence of transmurality, infarct size, and severe microvascular obstruction on left ventricular remodeling and function after primary coronary angioplasty. Am J Cardiol 98 (2006) 1033-1040
5. Steinhubl S.R., Talley J.D., Braden G.A., Tcheng J.E., Casterella P.J., Moliterno D.J., Navetta F.I., Berger P.B., Popma J.J., Dangas G., Gallo R., Sane D.C., Saucedo J.F., Jia G., Lincoff A.M., Theroux P., Holmes D.R., Teirstein P.S., and Kereiakes D.J. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 103 (2001) 2572-2578
6. Chesebro J.H., Knatterud G., Roberts R., Borer J., Cohen L.S., Dalen J., Dodge H.T., Francis C.K., Hillis D., and Ludbrook P. Thrombolysis In Myocardial Infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 76 (1987) 142-154
7. van't Hof A.W., Liem A., Suryapranata H., Hoorntje J.C., de Boer M.J., Zijlstra F., and Zwolle Myocardial Infarction Study Group. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Circulation 97 (1998) 2302-2306
8. Larose E., Cote J., Rodes-Cabau J., Noel B., Barbeau G., Bordeleau E., Miro S., Brochu B., Delarochelliere R., and Bertrand O.F. Contrast-enhanced cardiovascular magnetic resonance in the hyperacute phase of ST-elevation myocardial infarction. Int J Cardiovasc Imaging 25 (2009) 519-527
9. de Prado A.P., Fernandez-Vazquez F., Cuellas J.C., Alonso-Orcajo N., Carbonell R., Pascual C., Olalla C., Diego A., de Miguel A., and Calabozo R.G. Association between level of platelet inhibition after early use of abciximab and myocardial reperfusion in ST-elevation acute myocardial Infarction treated by primary percutaneous coronary intervention. Am J Cardiol 97 (2006) 798-803
10. Bellandi F., Maioli M., Gallopin M., Toso A., and Dabizzi R.P. Increase of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary occlusion in patients with acute myocardial infarction treated with primary coronary intervention. Catheter Cardiovasc Interv 62 (2004) 186-192
11. Tcheng J.E., Ellis S.G., George B.S., Kereiakes D.J., Kleiman N.S., Talley J.D., Wang A.L., Weisman H.F., Califf R.M., and Topol E.J. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 90 (1994) 1757-1764
12. Ernst N.M., Suryapranata H., Miedema K., Slingerland R.J., Ottervanger J.P., Hoorntje J.C., Gosselink A.T., Dambrink J.H., de Boer M.J., Zijlstra F., and van't Hof A.W. Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction. J Am Coll Cardiol 44 (2004) 1187-1193
13. Bertrand O.F., De Larochelliere R., Rodes-Cabau J., Proulx G., Gleeton O., Nguyen C.M., Dery J.P., Barbeau G., Noel B., Larose E., Poirier P., and Roy L. A randomized study comparing same-day home discharge and abciximab bolus only to overnight hospitalization and abciximab bolus and infusion after transradial coronary stent implantation. Circulation 114 (2006) 2636-2643
14. Bertrand O.F., Rodes-Cabau J., Larose E., Nguyen C.M., Roy L., Dery J.P., Courtis J., Nault I., Poirier P., Costerousse O., and De Larochelliere R. One-year clinical outcome after abciximab bolus-only compared with abciximab bolus and 12-hour infusion in the Randomized EArly Discharge after Transradial Stenting of CoronarY Arteries (EASY) study. Am Heart J 156 (2008) 135-140
15. Mahmud E., Cavendish J.J., Tsimikas S., Ang L., Nguyen C., Bromberg-Marin G., Schnyder G., Keramati S., Palakodeti V., Penny W.F., and DeMaria A.N. Elevated plasma fibrinogen level predicts suboptimal response to therapy with both single- and double-bolus eptifibatide during percutaneous coronary intervention. J Am Coll Cardiol 49 (2007) 2163-2171
16. Montalescot G., Wiviott S.D., Braunwald E., Murphy S.A., Gibson C.M., McCabe C.H., and Antman E.M. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 373 (2009) 723-731
17. Collet J.P., Montalescot G., Lesty C., Mishal Z., Soria J., Choussat R., Drobinski G., Soria C., Pinton P., Barragan P., and Thomas D. Effects of abciximab on the architecture of platelet-rich clots in patients with acute myocardial infarction undergoing primary coronary intervention. Circulation 103 (2001) 2328-2331
18. Collet J.P., Montalescot G., Lesty C., Soria J., Mishal Z., Thomas D., and Soria C. Disaggregation of in vitro preformed platelet-rich clots by abciximab increases fibrin exposure and promotes fibrinolysis. Arterioscler Thromb Vasc Biol 21 (2001) 142-148
19. Marciniak Jr. S.J., Mascelli M.A., Furman M.I., Michelson A.D., Jakubowski J.A., Jordan R.E., Marchese P.J., and Frelinger A.L. An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates. Thromb Haemost 87 (2002) 1020-1025
20. Sezer M., Oflaz H., Goren T., Okcular I., Umman B., Nisanci Y., Bilge A.K., Sanli Y., Meric M., and Umman S. Intracoronary streptokinase after primary percutaneous coronary intervention. N Engl J Med 356 (2007) 1823-1834
21. Deibele A.J., Kirtane A.J., Pinto D.S., Lucca M.J., Neva C., Shui A., Murphy S.A., Tcheng J.E., and Gibson C.M. Intracoronary bolus administration of eptifibatide during percutaneous coronary stenting for non ST elevation myocardial infarction and unstable angina. J Thromb Thrombolysis 22 (2006) 47-50
22. Wohrle J., Grebe O.C., Nusser T., Al-Khayer E., Schaible S., Kochs M., Hombach V., and Hoher M. Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty. Circulation 107 (2003) 1840-1843
23. Yang X.C., Zhang D.P., Wang L.F., Xu L., Ge Y.G., Wang H.S., Li W.M., Ni Z.H., Xia K., Lian Y., Xue Y.L., and Ma L.X. [Effects of intracoronary or intravenous tirofiban administration in patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention]. Zhonghua Xin Xue Guan Bing Za Zhi 35 (2007) 517-522
24. Bertrand O.F., Rodes-Cabau J., Larose E., Nguyen C.M., Dery J.P., Proulx G., Roy L., Poirier P., Costerousse O., and De Larochelliere R. Effects of intracoronary compared to intravenous abciximab administration in patients undergoing transradial percutaneous coronary intervention: a sub-analysis of the EASY trial. Int J Cardiol 136 (2009) 165-170
25. Galache Osuna J.G., Sanchez-Rubio J., Calvo I., Diarte J.A., Lukic A., and Placer L.J. [Does intracoronary abciximab improve the outcome of percutaneous coronary interventions? A randomized controlled trial]. Rev Esp Cardiol 59 (2006) 567-574
26. Thiele H., Schindler K., Friedenberger J., Eitel I., Furnau G., Grebe E., Erbs S., Linke A., Mobius-Winkler S., Kivelitz D., and Schuler G. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial. Circulation 118 (2008) 49-57
27. Spaulding C., Henry P., Teiger E., Beatt K., Bramucci E., Carrie D., Slama M.S., Merkely B., Erglis A., Margheri M., Varenne O., Cebrian A., Stoll H.P., Snead D.B., and Bode C. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 355 (2006) 1093-1094
28. Gersh B.J., Stone G.W., White H.D., and Holmes Jr. D.R. Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction: is the slope of the curve the shape of the future?. JAMA 293 (2005) 979-986